


• Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF,


• Rotolo F, Zhu CQ, Brambilla E, Graziano SL, Olaussen K, Le-Chevalier T, Pignon JP, Kratzke R, Soria JC, Shepherd FA, Seymour L, Michiels S, Tsao MS. Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and


2017


• Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel


2016


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statist Med n/a, 2016.
- Liedke PER, Tu D, Shepherd L, Chavarri-Guerra Y, Pritchard KL, Stearns V, Goss PE. New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.


- Tang PA, Hay AE, O'Callaghan CJ, Mittmann N, Chambers CR, Pater JL, Leighl NB. Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada. Current Oncology 23:
s7-s13, 2016.


- Bartlett JMS, Nielsen TO, Gao D, Gelmon KA, Quintayo MA, Starczynski J, Han L, Burnell MJ, Levine MN, Chen BE, Shepherd LE, Chapman JW. TLE3 is not a predictive


preoperative chemoradiation plus perioperative ECF chemotherapy for resectable
gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC

- Lin NU, Lee EQ, Aoyama H, Barani IJ, Barbioriak DP, Baumert BG, Bendszus M, Brown
  PD, Camidge DR, Chang SM, Dancey J, de Vries EGE, Gaspar LE, Harris GJ, Hodi FS,
  Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R,
  Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY. Response assessment criteria for
  brain metastases: proposal from the RANO group. The Lancet Oncology 16: e270-e278,
  2015.

  Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG

- Lohmann A, Chapman JA, Burnell M, Levine M, Tsvetkova E, Pritchard K, Gelmon K,
  Shepherd L, Goodwin P. Prognostic associations of 25 hydroxy vitamin D in NCIC CTG
  MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in

- Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M,
  Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MKB, Hayter C, Jovic G,
  Hiltz A, Hetherington J, Sathyja Y, Barber JBP, McKenzie M, El-Sharkawi S, Souhami L,
  Hardman PDJ, Chen BE, Warde P. Final Report of the Intergroup Randomized Study of
  Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-
  Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol 33:
  2143-50, 2015.

- McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sniege N,
  EA, Wilcox JL, Vallow LA, Small W, Pu AT, Kerlin K, White J. RTOG 9804: A
  Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing

- Monzon JG, Hay AE, McDonald GT, Pater JL, Meyer RM, Chen E, Chen BE, Dancey
  JE. Correlation of single arm versus randomised phase 2 oncology trial characteristics

- Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E,
  MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan
  R, Parmar MK, Perren TJ. Standard chemotherapy with or without bevacizumab for
  women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase

  Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

- Péron J, Roy P, Ding K, Parulekar WR, Roche L, Buyse M. Assessing the benefit-risk of
  new treatments using generalised pairwise comparisons: the case of erlotinib in

- Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR,
  Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, Squire J, Tsao MS, Kamel-Reid S,
  Banerji S, Tu D, Powers J, Hausman DF, Mason WP. Phase II study of PX-866 in


• Sweeney C, Nakabayashi M, Regan M, Xie W, Hayes J, Keating N, Li S, Philipson T,


- Goldstein DP, Ringash J, Bissada E, Jaquet Y, Irish J, Chepeha D, Davis AM.


- Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice. Eur J Can 50: 2303-8, 2014.

2013


- Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S,
Caplan S, Foo A, Walsh W, Leber B. A Phase I/II Study of Sorafenib (BAY 43-9006) In Combination with Low Dose Cytarabine (LDAC) In Elderly Patients with AML or High-Risk MDS from the NCIC Clinical Trials Group: Trial IND.186. Leuk Lymphoma 54: 760-6, 2013.

- Seymour LK, Calvert AH, Lobbezoo MW, Eisenhauer EA, Giaccone G. Design and conduct of early clinical studies of two or more targeted anticancer therapies:


- de Almeida JR, Vescan AD, Gullane PJ, Gentili F, Lee JM, Lohfeld L, Ringash J, Thoma...


- Jiang S, Tu D. Inference on the probability as a measurement of treatment effect under a density ratio model and random censoring. Computational Statistics and Data Analysis 56: 1069-78, 2012.


- Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kaern J, Havsteen H,


- Peng Y, Xu J. An extended cure model and model selection. Lifetime Data Anal 18:


2011


Fleschner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, Farley A, Jansz K, Siemens DR, Trpkov K, Lacombe L, Gleave M, Tu D, Parulekar WR. Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of


- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrilis IL, Pritchard KI. Topoisomerase II alpha protein and responsiveness of breast
Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.


- Rustin GJS, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois

- Sargent D, Shi Q, Yothers G, Van CE, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de GA. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-6, 2011.


**2010**


308-12, 2010.


2009


specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27: 2450-6, 2009.


2008


• Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol Oncol 108: 100-5, 2008


• Goffin JR, Tu D. Phase II stopping rules that employ response rates and early


2007


- Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M,


• Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung


Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, MacLean M, Drolet DW, Rusk J, Seymour LK. A phase I, first in man study of OSI-7836


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krock J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits


- Vermorken JB, Parmar MKB, Brady MF, Eisenhauer EA, Hogberg T, Ozols RF, Rochon


2004


- Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst S, Walsh W, Wainman N, Colevas AD, Eisenhauer EA. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 22(3): 315-22,


Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliarid JA, Bushey TIL, Nair S, Christensen B. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and NCIC Clinical Trials Group


2003


- Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R, Crump M. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a


• Yee K, Pater J, Pho L, Zee B, Siu L. Enrollment of older patients in cancer treatment


Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G,


2001


2000


1999


- Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.

1998

- Eisenhauer EA, Ten Bokkel-Huinink WW, Swenerton KD, Gianni L, Myles J, van der


1997


- Osoba D, Aaronson N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.


- Sawka CA, Pritchard KI, Shelley W, DeBoer G, Paterson AHG, Meakin JW, Sutherland


1996


- Denk S, Eisenhauer E. Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.

- Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD,


1994


1993


1993.


1992


1991


1990


1989


1988


1987


1986


1986.


1985


1984


